eMedonline delivers its patented platform to Healthcare Providers, Payers, Pharmaceutical Manufacturers, and Specialty Pharmacies enabling them to significantly improve their patients' medication compliance, facilitate enhanced transitions of care and chronic disease management, and obtain actionable data mining opportunities for drug surveillance and research.
Transitions of Care
Managing Congestive Heart Failure (CHF), Pneumonia (PN) and Acute Myocardial Infarction (AMI) patients as they transition from the hospital to their home or an ambulatory care setting is receiving significant attention as a result of penalties to be levied by the Centers for Medicare & Medicaid Services (CMS). Among Medicare patients, 20% are rehospitalized within 30 days, and two‐thirds are rehospitalized or dead within a year. Many rehospitalizations result from care system failures in the transition from hospital to the next care setting.
Chronic Disease Management
Medication adherence has been called the Achilles heel of modern healthcare. The average rate of adherence is only 50% after one year and continues to decline. It is associated with nearly 70% of all medication-related hospital admissions in the U.S., at an estimated annual cost well over $100 billion. Nonadherence issues are particularly troublesome with oral chemotherapeutic medications, which are increasingly entering the market, and which often have severe toxicities and narrow therapeutic indices. A review of adherence published in the Journal of the National Cancer Institute found that up to 80% of cancer patients failed to follow their prescriptions.
The pharmaceutical industry is estimated to spend over $50 billion a year on the research and development of new drugs, and the cost of bringing a new drug to market is estimated at $1 billion. Each day a drug is delayed from reaching the market, the sponsor loses up to $8 million. Only six percent of clinical trials are completed on time, and 72% of trials run over schedule by more than one month. Only one in five drugs is approved for sale in the U.S., which has a direct impact on ROI for drug manufacturers.
Specialty drugs treat a wide array of people at every age and stage of life. They are used to treat diseases that include cancer, Hepatitis C, multiple sclerosis (MS), rheumatoid arthritis (RA), and Chron's Disease. Medication nonadherence for these diseases is high (63% for MS, 50% for RA, and up to 80% for cancer). This results in emergency room visits, complications, hospitalizations, and the need for medications to treat secondary conditions, estimated to cost $250 billion.